Redhill Biopharma Ltd(RDHL)

盘后8.340.000.00%17:02 EDT

8.34+0.33+4.12%

社区社区
资讯资讯
资料资料
公告公告

- 最新
- 推荐
公司概况
公司名称
Redhill Biopharma Ltd
所属市场
NASDAQ
成立日期
- -
员工人数
- -
办公地址
- -
公司网址
http://www.redhillbio.com
邮政编码
- -
联系电话
- -
联系传真
- -
公司概况
Redhill Biopharma Ltd.于2009年8月3日在以色列注册成立。该公司是一家专业生物制药公司，主要专注于胃肠道和传染病。该公司的主要目标是通过在美国的商业存在，成为一家领先的专业生物制药公司，支持在美国上市的现有和潜在的其他产品的商业化，以及未来可能的治疗候选药物的商业化（如果获得批准的话）。该公司目前主要致力于在美国实现GI相关产品Talicia（奥美拉唑、阿莫西林和利福布汀）和Aemcolo（利福霉素）的商业化。
- 08-16
  SEC问询函
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 06-20
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 04-08
  年度报告
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 02-15
  SEC问询函
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 02-09
  招股说明书
  Form F-1 - Registration statement for certain foreign private issuers
  Form F-1 - Registration statement for certain foreign private issuers
- 02-02
  超过5%披露
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 02-01
  超过5%披露
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
  Form SC 13G - Statement of acquisition of beneficial ownership by individuals
- 01-08
  超过5%披露
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
  Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
- 2023-10-26
  SEC问询函
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2023-08-10
  SEC问询函
  Form CORRESP - Correspondence
  Form CORRESP - Correspondence
- 2023-06-29
  员工持股计划
  Form S-8 - Securities to be offered to employees in employee benefit plans
  Form S-8 - Securities to be offered to employees in employee benefit plans
- 2023-04-28
  年度报告
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
- 2023-01-13
  超过5%披露
  SC 13G - Statement of acquisition of beneficial ownership by individuals
  SC 13G - Statement of acquisition of beneficial ownership by individuals
- 2022-06-27
  员工持股计划
  S-8 - Securities to be offered to employees in employee benefit plans
  S-8 - Securities to be offered to employees in employee benefit plans
- 2022-03-17
  年度报告
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
  20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

分时
5日
日
周
月

最高

8.35

今开

8.01

量比

0.64

最低

8.01

昨收

8.01

换手率

0.76%

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

Redhill Biopharma Ltd(RDHL)

公司概况

热议股票